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Abstract  20 
Quinolones, such as the antimalarial atovaquone, are inhibitors of the malarial 21 
mitochondrial cytochrome bc1 complex, a target critical to the survival of both liver and 22 
blood stage parasites, making these drugs useful as both prophylaxis and treatment. 23 
Recently, several derivatives of endochin have been optimised to produce novel 24 
quinolones that are active in vitro and in animal models. While these quinolones exhibit 25 
potent ex vivo activity against Plasmodium falciparum and P. vivax, their activity against 26 
the zoonotic P. knowlesi is unknown. We screened several of these novel endochin-like 27 
quinolones (ELQs) for their activity against P. knowlesi in vitro, and compared this with 28 
their activity against P. falciparum tested under identical conditions. We demonstrate that 29 
ELQs are potent against P. knowlesi (EC50 values <117 nM), and equally effective against 30 
P. falciparum. We then screened select quinolones and partner drugs using a longer 31 
exposure (2.5 life cycles), and show that proguanil is 10-fold less potent against P. 32 
knowlesi when compared with P. falciparum, while the quinolones demonstrate similar 33 
susceptibility. Finally, we used isobologram analysis to compare combinations of the ELQs 34 
with either proguanil or atovaquone. We show that all quinolone combinations with 35 
proguanil are synergistic against P. falciparum. However, against P. knowlesi, no evidence 36 
of synergy between proguanil and the quinolones was found. Importantly, combining the 37 
novel quinolone ELQ-300 with atovaquone, was synergistic against both species. Our data 38 
identify potentially important species differences in proguanil susceptibility and its 39 
interaction with quinolones, and support the ongoing development of novel quinolones as 40 
potent antimalarials that target multiple species.   41 
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Introduction.  42 
Malaria continues to exert a significant burden on humanity with around 228 million 43 
infections estimated in 2018, an increase from the 217 million infections estimated for 44 
2014 (1). The World Health Organisation currently recommends artemisinin-based 45 
combination therapies (ACT) as the first-line treatment of uncomplicated malaria. These 46 
are composed of a potent, but short-lived artemisinin derivative combined with a long-47 
acting partner drug (2). By using drugs in combination with different targets the intention is 48 
to delay the emergence of resistance to the individual components. However, recent 49 
evidence has emerged in the Greater Mekong subregion of resistance to both artemisinin 50 
(3, 4) and current partner drugs (5, 6). There is, therefore, an urgent need to develop new 51 
drugs and novel combination regimens before reduction in ACT efficacy occurs more 52 
widely.  53 
Quinolones have been investigated as potential antimalarial agents since the Second 54 
World War (7). However, the only successful candidate from this class to emerge from 55 
these studies as an antimalarial has been atovaquone. Atovaquone targets the 56 
mitochondrial cytochrome bc1 complex (8, 9) and is highly potent against Plasmodium 57 
species. Unfortunately, recrudescence after atovaquone monotherapy occurs rapidly. 58 
Atovaquone is therefore used in combination with a synergistic partner drug, proguanil 59 
(10), but even this combination is vulnerable to mutations in pfcytb especially in areas of 60 
cycloguanil resistance (11, 12). Although the target of proguanil is not currently known, 61 
proguanil has recently been shown to increase in potency against Plasmodium falciparum 62 
after a longer in vitro exposure (13). Considering that the mitochondrial targeting 63 
atovaquone-proguanil combination differs in its mechanism of resistance to the 64 
components of current ACT, this combination has been investigated as an alternative 65 
treatment of multidrug resistant malaria infections (14), though it should be noted that the 66 
atovaquone-proguanil combinations tested performed poorly (only 90-92% effective at 42 67 
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days post-treatment) in that region of Cambodia, and are unlikely to be useful as 68 
treatment. Furthermore, drugs targeting the mitochondria kill both liver- and blood-stage 69 
malaria infections, and so can be used for both prophylaxis and treatment. 70 
New quinolones based on endochin, a compound shown to be active at clearing avian 71 
malaria (15), have recently been synthesised and tested against malaria parasites (16-18). 72 
These endochin-like quinolones (ELQ) are equally effective in ex vivo blood stage screens 73 
against P. falciparum and P. vivax clinical field isolates, and are also effective against 74 
exoerythocytic forms of rodent and monkey (P. cynomolgi) malaria (16). However, the 75 
activity of ELQs against the zoonotic P. knowlesi, an increasingly important cause of 76 
human malaria in Southeast Asia, is unknown. Importantly, recent articles have identified 77 
differences in in vitro (19, 20) and ex vivo (21) susceptibility between P. knowlesi and P. 78 
falciparum to established and experimental antimalarial agents. In particular, in vitro 79 
studies demonstrated that P. knowlesi is up to 8-fold less susceptible than P. falciparum to 80 
inhibitors of dihydroorotate dehydrogenase (e.g., DMS265 (20)), 6-fold less susceptible to 81 
ATP4 inhibitors (e.g., cipargamin, SJ733 (19)), around 3-fold less susceptible to 82 
cladosporin and pentamidine, and 66-fold less susceptible to the oxaborole AN13762 (19). 83 
Conversely, P. knowlesi was shown to be 10-fold more susceptible to dihydrofolate 84 
reductase inhibitors (e.g., pyrimethamine, cycloguanil (20)), around 4.5-fold more 85 
susceptible to ganaplacide (KAF156), and over 3-fold more susceptible to halofantrine 86 
(19). In spite of the reduced susceptibility of P. knowlesi compared with P. falciparum, 87 
many antimalarials remain potent against P. knowlesi in vitro (e.g., 6 nM for cipargamin), 88 
and any clinical significance of these reported species differences is yet to be established. 89 
Here we test the in vitro activity of endochin and an ELQ series for activity against P. 90 
knowlesi, and compare this to the activity of a quinbolone-sensitive, reference P. 91 
falciparum line (3D7) under identical experimental conditions, exposed for a single asexual 92 
erythrocytic parasite life cycle (i.e., 27 h for our P. knowlesi A1-H.1 clone (22) and 48 h for 93 
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P. falciparum 3D7 clone). We then assess the impact of longer exposures to proguanil and 94 
select ELQs on the susceptibility of our P. knowlesi and P. falciparum lines. Finally, we use 95 
isobologram analysis in vitro to test for evidence of synergy between proguanil, or 96 
atovaquone, and ELQ compounds against both species.   97 
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Results and Discussion. 98 
Endochin and six endochin-like quinolones (ELQ) were screened under identical in vitro 99 
conditions across one complete asexual erythrocytic life cycle against both the P. knowlesi 100 
A1-H.1 and the P. falciparum 3D7 lines (Table 1). All but one (ELQ-271) of the ELQ 101 
compounds were potent against the P. knowlesi line with EC50 values under 100 nM. The 102 
potency of endochin and the ELQ compounds was similar against both P. knowlesi and P. 103 
falciparum, with a less than two-fold difference observed between species. With the 104 
exception of ELQ-300 all the quinolones screened were more active against P. falciparum 105 
(Table 1), though for endochin and ELQ-331 the differences were not significant (p = 106 
0.6233 and p = 0.5014, respectively; Table 1). ELQ-400 and ELQ-480 are both active at 107 
under 10 nM making them more potent than chloroquine but not as active as 108 
dihydroartemisinin (Table 1). 109 
P. falciparum exhibits significantly enhanced susceptibility to proguanil when incubated for 110 
more than one life cycle (13). Therefore, in preparation for in vitro combination analysis 111 
(isobolograms), we screened ELQ-300 and ELQ-400 as well as proguanil and atovaquone 112 
using a longer incubation time (2.5 life cycles). We had previously found no activity for 113 
proguanil at 10 µM (the highest concentration we tested) after a single life cycle exposure 114 
against either P. knowlesi or P. falciparum (data not shown). However, with a longer 115 
exposure (2.5 cycles), we observed an EC50 value for proguanil of 2461 ± 236 nM for P. 116 
knowlesi, over ten-fold higher than the EC50 value that we observed for P. falciparum 3D7 117 
clone (228 ± 29 nM; Table 2). We expect natural variability within our EC50 values as our 118 
assays are run using asynchronous parasite populations, and because the parasites have 119 
different life cycle lengths, meaning drugs are exposed longer to P. falciparum per life 120 
cycle than for P. knowlesi. Hence, we only consider a greater than three-fold change in 121 
EC50 between species as a potentially important species difference (19).  122 
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Atovaquone, ELQ-300, and ELQ-400 were all more potent after the longer exposure. 123 
Atovaquone potency increased around three-fold from 2.5 nM (20) to 0.7 nM (Table 2), 124 
and was not significantly different between species. ELQ-300 and ELQ-400 were also 125 
more potent after longer in vitro exposures (Tables 1 and 2). Both compounds were now 126 
more active against P. knowlesi than P. falciparum (p < 0.0072), though the fold difference 127 
between species was small (< 3-fold). 128 
Based on these data, combination studies were then designed to explore the in vitro 129 
interactions between the compounds. These experiments were also run over multiple life 130 
cycles to take into account the increased potency of proguanil after longer exposures (13). 131 
As has been shown previously (10, 13, 23), atovaquone is synergistic in combination with 132 
proguanil against P. falciparum (Fig. 1A, Table 3). The investigational quinolones ELQ-300 133 
and ELQ-400 were also synergistic when combined with proguanil against our P. 134 
falciparum line (Fig. 1B, 1C), confirming previous observations for ELQ-300 (16). 135 
Surprisingly, neither atovaquone, nor the ELQ compounds demonstrated a synergistic 136 
interaction in combination with proguanil when tested against P. knowlesi. Instead, all 137 
interactions were additive/indifferent (Fig. 1D-F, Table 3). Without knowing the target of 138 
proguanil or understanding its mechanism of action, it is not possible to speculate on the 139 
reason for this species difference. Clearly, the ten-fold lower proguanil activity against P. 140 
knowlesi (not observed with quinolone activity) coupled with the lack of synergism with 141 
quinolones suggest a species difference in the inhibitory activity of this biguanide.  142 
An alternative drug combination strategy for quinolones is suggested by recent data 143 
indicating that quinolones can inhibit the cytochrome bc1 complex (cyt bc1) at either the 144 
quinol oxidase (Qo) or quinone reductase (Qi) site (24). Atovaquone and ELQ-400 are Qo 145 
site inhibitors (8, 24), while ELQ-300 was shown to target the Qi site (24). Isobolograms 146 
combining a Qo site inhibitor (atovaquone) with a Qi site inhibitor (ELQ-300) have 147 
previously demonstrated a moderately synergistic interaction against P. falciparum strain 148 
8 
 
D6 in vitro (25). We confirm this moderately synergistic interaction between atovaquone 149 
and ELQ-300 against our P. falciparum 3D7 line (Fig. 2A) and show also a moderately 150 
synergistic interaction with this combination against our P. knowlesi line (Fig. 2C and Table 151 
3). Combinations of atovaquone with ELQ-400, both inhibitors of the Qo site, were 152 
additive/indifferent against P. falciparum (Fig. 2B) and P. knowlesi (Fig. 2D and Table 3). 153 
Therefore, a more appropriate combination partner for the Qo site inhibitor, atovaquone, 154 
should perhaps be a Qi site inhibitor (such as ELQ-300) which (a) is considerably more 155 
potent than proguanil, and (b) demonstrates moderate synergism in combination with 156 
atovaquone against both P. falciparum and P. knowlesi species in vitro, unlike 157 
combinations with proguanil. 158 
In vivo, proguanil is metabolized to cycloguanil by the liver cytochrome P450 (CYP2C19) 159 
(26, 27). Cycloguanil is an inhibitor of the enzyme dihydrofolate reductase (DHFR), a 160 
component of the folate pathway in malaria parasites. Thus, the drug combination 161 
atovaquone-proguanil actually serves as a triple drug therapy of atovaquone (cytochrome 162 
bc1 inhibitor), proguanil (target unknown), and its metabolite cycloguanil (DHFR inhibitor). 163 
Cycloguanil, like atovaquone, has been shown to be highly potent against P. knowlesi in 164 
vitro (20). Therefore, even though antagonistic interactions between atovaquone and 165 
cycloguanil have been described in vitro (13), the low nanomolar potency of both 166 
cycloguanil and atovaquone (20) should still support this combination for P. knowlesi 167 
infections, despite the reduced activity of proguanil, and its lack of synergy reported here.  168 
In light of the above-mentioned data, the recent strategy proposed to block the cyclization 169 
of proguanil, thereby reducing its metabolism to cycloguanil, ought to be approached with 170 
caution (13). In the absence of cycloguanil, and with the reduced activity of proguanil, 171 
atovaquone may be exposed as a monotherapy against P. knowlesi infections. It will 172 
therefore be critical to screen the cyclization blocked tert-butyl proguanil (13) for its activity 173 
against P. knowlesi, and to test it in combination studies with quinolones in this species.   174 
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To our knowledge this is the first study to demonstrate differences in drug interactions 175 
between two human malaria species. We have reported previously that compounds in 176 
human trials for malaria (e.g., DSM 265, cipargamin) exhibit reduced in vitro susceptibility 177 
to P. knowlesi (19, 20), similar to our observations here for proguanil. Considering all new 178 
malaria treatments will likely comprise of combinations of drugs, it will be critical to ensure 179 
that new combinations involving compounds with reduced susceptibility against P. 180 
knowlesi, interact similarly across species. 181 
Resistance to 10 nM atovaquone (5 × EC50) is induced readily in vitro after exposure to 182 
only 105 parasites of the P. falciparum clone W2, or exposure to 106 parasites of the 3D7 183 
or FCR3 clones (28). Furthermore, exposure of 108 parasites of the P. falciparum Dd2 184 
clone to 10 nM atovaquone (10 × EC50) also selected resistant parasites, but no resistant 185 
parasites emerged to 150 nM ELQ-300 (also 10 × EC50) at the same inoculum (16). This 186 
suggests that the new endochin-like quinolones demonstrate a lower propensity to induce 187 
resistance in that parasite clone (16). Similar tests should now be performed on the P. 188 
knowlesi A1-H.1 line and other newly adapted P. knowlesi lines to explore the propensity 189 
of this species to develop resistance to the various quinolones.  190 
In conclusion, novel endochin-like quinolones exhibit strong antimalarial activity (EC50 191 
values <117 nM) against P. knowlesi in vitro, and are equipotent against P. falciparum. We 192 
demonstrate for the first time that quinolone combinations with proguanil lack synergy 193 
against P. knowlesi in vitro, suggesting distinct mechanisms of action in the malaria 194 
parasites. In contrast, combinations of inhibitors targeting the cytochrome bc1 complex at 195 
the Qo site (e.g., atovaquone) with those targeting the Qi site (e.g., ELQ-300) show 196 
moderate synergism against both species.  197 
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Materials and Methods. 198 
Drugs and experimental compounds. Proguanil hydrochloride (product no. G7048) was 199 
purchased from Sigma-Aldrich UK. Atovaquone was obtained from the Medicines for 200 
Malaria Venture. Endochin-like quinolones were synthesised as described below. 201 
Chemical Synthesis. The chemical synthesis of endochin was performed as originally 202 
described by Andersag and others in 1948 (29), while methods for ELQ-271 and ELQ-300 203 
were described by Nilsen et al. in 2014 (17). Methods for preparing ELQ-316 were described 204 
by Doggett et al. in 2012 (30).  Preparation of ELQ-331 was described previously by Frueh 205 
et al. (31).  Chemical synthesis of ELQ-400 proceeded by the methods of Stickles and 206 
coworkers in 2015 (32).  Synthesis and characterization of ELQ-480 are described below. 207 
5-fluoro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)quinolin-208 
4(1H)-one (ELQ-480): ELQ-480 was synthesized according to the methods described by 209 
Nilsen et al. in 2014 (17). Purity of ELQ-480 was assessed as >95% by proton NMR. 1H-210 
NMR spectra were obtained using a Bruker AMX-400 NMR spectrometer operating at 211 
400.14 MHz in DMSO D6.  The NMR raw data were analyzed using the iNMR Spectrum 212 
Analyst software. Proton chemical shifts were reported in parts per million units (ppm), () 213 
relative to the residual proton at 2.54 ppm in deuterated DMSO D6. J coupling constants 214 
values are in Hertz (Hz). Coupling constants for 19F NMR operating at 376 MHz were also 215 
obtained for compounds containing fluorine elements for additional validation of structure.  216 
NMR spectrum of ELQ-480: 1H-NMR (400 MHz; DMSO-d6):   11.55 (s, 1H), 7.42 (d, J = 8.1 217 
Hz, 2H), 7.25 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 8.7 Hz, 2H), 7.06 (d, J = 8.2 Hz, 2H), 6.76 (s, 218 
1H), 6.63 (d, J = 13.3 Hz, 1H), 3.85 (s, 3H), 2.18 (s, 3H). 219 
Parasite Culture. P. knowlesi parasites (clone A1-H.1) and P. falciparum parasites (clone 220 
3D7) were grown in RPMI 1640 supplemented with 25 mM HEPES, 25 mM Na2HCO3, 10 221 
mM D-glucose, 2 mM L-glutamine, 50 mg/L hypoxanthine, 25 mg/L gentamicin sulphate, 5 222 
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g/L Albumax II and 10% (v/v) donor horse serum (Pan Biotech, P30-0702). All parasites 223 
were grown in human A+ red blood cells (National Health Blood and Transplant, UK). 224 
Parasites were incubated in sealed flasks at 37ºC under a culture gas mixture of 96% N2, 225 
3% CO2 and 1% O2. 226 
Growth inhibition assays and isobologram testing. Drug susceptibility was assessed 227 
precisely as described previously with parasites exposed to the drugs for one complete life 228 
cycle (27 h for P. knowlesi and 48 h for P. falciparum) or 2.5 life cycles (68 h for P. 229 
knowlesi and 120 h for P. falciparum) (19). Drug combination studies were performed as 230 
described previously (19, 23), with the exception that parasites were exposed to drugs for 231 
2.5 cycles instead of one life cycle, and the starting parasitaemia was reduced to 0.5% 232 
while maintaining the haematocrit at 1%. The Fractional Inhibitory Concentrations (FICs) 233 
were calculated as described previously (33). The SYBR green I method was used to 234 
determine parasite viability (19, 34).   235 
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Table 1: Comparison of the in vitro susceptibility of Plasmodium knowlesi (clone A1-H.1) 382 
and Plasmodium falciparum (clone 3D7) exposed to novel endochin-like quinolones for 383 
one complete life cycle. 384 
Compound 
EC50 values (nM) Fold 
Difference 
(Pk/Pf) 
P valueΨ P. knowlesi A1-H.1 
27 h exposure 
P. falciparum 3D7 
48 h exposure 
Endochin 18.9 ± 1.2 18.1 ± 0.5 1.04 0.6233 
ELQ-271 117 ± 12 64.5 ± 3.1 1.81 0.0081 
ELQ-300 15.4 ± 0.9 23.1 ± 1.2 0.67 0.0215 
ELQ-316 47.1 ± 2.6 33.5 ± 2.3 1.41 0.0097 
ELQ-331 49.0 ± 6.2 45.4 ± 1.6 1.08 0.5014 
ELQ-400 6.80 ± 0.26 4.95 ± 0.26 1.37 0.0030 
ELQ-480 7.06 ± 0.32 5.81 ± 0.26 1.22 0.0433 
Chloroquine 33.1 ± 2.0 17.7 ± 1.3 1.87 <0.0001 
Dihydroartemisinin 1.52 ± 0.07 3.64 ± 0.42 0.42 0.0112 
EC50 data are presented as mean ± SEM from at least 4 experiments each performed in 385 
duplicate. Ψ p values are calculated by comparing EC50 values for P. knowlesi versus P. 386 
falciparum using Student’s two-tailed paired t-test. 387 
  388 
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Table 2: Comparison of the in vitro susceptibility of Plasmodium knowlesi (clone A1-H.1) 389 
and Plasmodium falciparum (clone 3D7) exposed to proguanil and select quinolones for 390 
two and a half life cycles. 391 
Compound 
EC50 values (nM) Fold 
Difference 
(Pk/Pf) 
P valueΨ P. knowlesi A1-H.1 
68 h exposure 
P. falciparum 3D7 
120 h exposure 
Proguanil 2461 ± 236 228 ± 29 10.79 0.0007 
Atovaquone 0.71 ± 0.02 0.74 ± 0.09 0.99 0.1211 
ELQ-300 5.31 ± 0.3 15.29 ± 1.2 0.35 0.0011 
ELQ-400 1.32 ± 0.2 2.66 ± 0.3 0.50 0.0072 
EC50 data are presented as mean ± SEM from at least 3 experiments each performed in 392 
duplicate. Ψ p values are calculated by comparing EC50 values for P. knowlesi versus P. 393 
falciparum using Student’s two-tailed unpaired t-test. 394 
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Table 3: Mean fractional inhibitory concentrations (FICs) for the drug combinations tested 396 
in this study (Fig. 1 and Fig. 2). 397 
Combination tested 
Mean FICa 
P. knowlesi A1-H.1 P. falciparum 3D7 
Proguanil: Atovaquone 0.986 (0.949-1.024) ADDb 0.545 (0.503-0.586) SYN 
Proguanil: ELQ-300 1.077 (0.970-1.184) ADD 0.660 (0.619-0.700) SYN 
Proguanil: ELQ-400 0.995 (0.858-1.132) ADD 0.631 (0.571-0.690) SYN 
   
Atovaquone: ELQ-300 0.867 (0.814-0.920) M-SYN 0.816 (0.785-0.848) M-SYN 
Atovaquone: ELQ-400 0.980 (0.961-0.998) ADD 1.016 (0.980-1.052) ADD 
a The mean FIC is calculated from all FICs within each experiment, and for all experiments 398 
performed. The mean is reported, with 95% confidence intervals in parentheses. 399 
b SYN = synergistic interaction, M-SYN = moderately synergistic interaction, and ADD = 400 
additive / indifferent interaction.  401 
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Figure 1: Comparison of the in vitro interaction of proguanil with select quinolones against 402 
P. falciparum (clone 3D7; Panels A-C) and P. knowlesi (clone A1-H.1; Panels D-F). 403 
Fractional Inhibitory Concentration (FIC) data are averaged from at least three 404 
independent experiments, each run in triplicate. Error bars show standard error of the 405 
mean (SEM). FIC values < 1.0 are considered synergistic, while FIC values = 1 are 406 
considered additive/indifferent. 407 
 408 
Figure 2: Comparison of the in vitro interaction of atovaquone with two endochin like 409 
quinolones against P. falciparum (clone 3D7; Panels A-B) and P. knowlesi (clone A1-H.1; 410 
Panels C-D). Fractional Inhibitory Concentration (FIC) data are averaged from three 411 
independent experiments, each run in triplicate. Error bars show standard error of the 412 
mean (SEM). FIC values < 1.0 are considered synergistic, while FIC values = 1 are 413 
considered additive/indifferent. 414 
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